What is Immusoft?
Immusoft Corporation is a pioneering biotechnology enterprise dedicated to the transformation of disease treatment through its proprietary Immune System Programming platform. By engineering a patient's own B cells to function as internal factories for gene-encoded medicines, the company is effectively redefining the parameters of personalized medicine. This approach allows for the continuous, systemic delivery of therapeutic proteins, offering a potential paradigm shift for patients suffering from chronic and rare diseases. Headquartered in Seattle, Washington, Immusoft operates at the intersection of immunology and genetic engineering, maintaining a market position that emphasizes long-term therapeutic efficacy and patient-centric innovation.
How much funding has Immusoft raised?
Immusoft has raised a total of $33.3M across 5 funding rounds:
Private Equity
$2.4M
Series A
$2.7M
Series B
$20M
Debt
$150K
Other Financing Round
$8M
Private Equity (2014): $2.4M, investors not publicly disclosed
Series A (2016): $2.7M, investors not publicly disclosed
Series B (2019): $20M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Other Financing Round (2023): $8M backed by The California Institute for Regenerative Medicine
Key Investors in Immusoft
The California Institute for Regenerative Medicine
CIRM is a state agency focused on accelerating stem cell, regenerative medicine, and gene therapy research to deliver transformative treatments for serious diseases.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Immusoft?
With the recent influx of capital, Immusoft is well-positioned to accelerate its clinical pipeline and scale its manufacturing capabilities. The strategic focus will likely shift toward navigating the complexities of regulatory approval and expanding the reach of its B-cell reprogramming technology into broader therapeutic indications. As the company matures, the emphasis will remain on validating the safety and durability of its gene-encoded medicine delivery system. Investors and industry observers will be closely monitoring the firm's ability to translate its foundational research into scalable, commercial-ready therapies that address significant unmet medical needs in the global healthcare market.
See full Immusoft company page
